Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Short One Director for NYSE Rules

NEW YORK (GenomeWeb News) – The New York Stock Exchange has notified Bio-Rad Laboratories that it is not in compliance with exchange rules due to the resignation of a member of its board of directors and audit committee.

The NYSE said that the firm must have three independent directors of its audit committee to remain in compliance with market rules.

The recent resignation of Ruediger Naumann-Etienne left the company short one independent director for its audit committee. The firm has said that it is actively seeking a replacement for Naumann-Etienne and intends to regain compliance "as soon as practicable."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.